How to Give Albumin IV: Rates, Setup, and Monitoring

Intravenous albumin comes in two concentrations, 5% and 25%, and the choice between them determines nearly everything about how you set up the infusion, how fast you run it, and what you watch for. The 5% solution is roughly isotonic and acts as a straightforward volume expander, while the 25% solution is hyperoncotic and pulls fluid from the interstitial space into the bloodstream. Getting the rate, preparation, and monitoring right matters because mistakes with albumin can cause real harm, from fluid overload to a rare but documented risk of fatal hemolysis if the product is diluted incorrectly.

Choosing Between 5% and 25% Albumin

The concentration you hang shapes the clinical effect. A 5% albumin solution contains 5 grams of albumin per 100 mL. It behaves like plasma in terms of osmolarity and is used primarily to replace intravascular volume, for instance during hemorrhage, burn resuscitation, or when a patient needs bulk fluid. A 25% solution packs five times the protein into the same volume. Because it is hyperoncotic, it draws water from the tissues into the vascular space. That makes it the better choice when a patient needs oncotic support but cannot tolerate large fluid volumes, such as someone with decompensated liver disease or severe hypoalbuminemia with peripheral edema.

An older but informative study found that 50 grams of albumin expanded plasma volume by about 500 mL regardless of whether it was given as a 5%, 20%, or 25% solution. The expansion depended on the total albumin delivered and the patient’s existing plasma volume deficit, not on the concentration of the bag hanging on the pole.¹ In practical terms, this means giving 500 mL of 5% albumin and 100 mL of 25% albumin delivers the same mass of protein (25 g) and produces a comparable rise in circulating volume, but the 25% solution does it with far less total fluid.

Standard Infusion Rates

Rate guidelines vary somewhat by manufacturer and institution, but the general framework is consistent. For 5% albumin, a typical starting rate for a hemodynamically stable adult is 1 to 2 mL per minute, which can be increased to as fast as 5 to 10 mL per minute in emergencies such as active hemorrhagic shock. For 25% albumin, a common rate is about 1 mL per minute, and many protocols cap it at 2 to 3 mL per minute. The reasoning is simple: pushing a hyperoncotic solution too quickly pulls a surge of interstitial fluid into the vasculature and can overload the heart.

Two populations that consistently need slower rates are elderly patients and anyone with known cardiac dysfunction. In those patients, starting slower and titrating up after 15 to 30 minutes of stable vital signs is standard practice. Pediatric dosing is weight-based and institution-specific, and rates are generally much lower in absolute terms.

The first 15 minutes of any albumin infusion are the highest-risk window for an allergic or anaphylactic reaction. Many facilities require the infusion to begin at a reduced rate during this period, then permit a stepwise increase if the patient tolerates it. How fast you can ultimately run the infusion also depends on vascular access: a peripheral 20-gauge catheter simply cannot deliver the same flow as a central line, and pushing against resistance increases the risk of hemolysis.

Setup and Preparation

Albumin is supplied as a ready-to-use solution in glass bottles or flexible bags. It does not require reconstitution. Each unit has a clearly marked concentration, expiration date, and lot number. Before spiking the bag, check for cloudiness, discoloration, or particulate matter. Albumin should be a clear, slightly viscous amber liquid. Turbid or discolored solution should not be used.

Use a standard intravenous administration set with a vented spike for glass bottles, or a non-vented set for flexible containers. Most institutions do not require a blood filter for albumin, but some policies call for a standard inline filter. Confirm your facility’s protocol. The product is compatible with normal saline and 5% dextrose in water. You can run it through the same line or use either of those solutions as a flush.

The Sterile Water Rule

This is one area where a preparation mistake can be lethal. Some clinical situations call for diluting 25% albumin to a lower concentration. The diluent must be a physiologically osmolar solution like normal saline or 5% dextrose. It must never be sterile water for injection used alone. When 25% albumin is diluted with plain sterile water, the resulting solution becomes severely hypotonic. Infusing it causes red blood cells to swell and burst, a process called hemolysis. The CDC documented ten episodes of hemolysis linked to this exact error in the 1990s, including one death.² The bottles of sterile water and normal saline can look nearly identical on a supply shelf, so verifying the diluent is one of the most important safety checks during setup.

Timing and Storage

Albumin contains no preservative once the seal is broken. After puncturing the closure, the product should be started promptly and the infusion completed within four hours to minimize the risk of bacterial contamination. Unopened vials are stored at room temperature, generally between 20 and 25°C. They should not be frozen. If the solution has been stored in the refrigerator, allow it to come to room temperature before infusing, because cold albumin can cause discomfort at the infusion site and may affect flow rate.

Monitoring During and After the Infusion

Baseline vital signs, including blood pressure, heart rate, respiratory rate, and oxygen saturation, should be documented before starting. During the first 15 minutes, take vitals at least every 5 minutes. After that, frequency depends on the clinical context, but a reasonable default for a stable patient is every 15 to 30 minutes until the infusion is complete, and then once more 30 to 60 minutes afterward.

What you are watching for falls into three broad categories:

Allergic reactions: hives, flushing, itching, lip or throat swelling, wheezing, or a sudden drop in blood pressure. Stop the infusion immediately if any of these appear.
Fluid overload: rising blood pressure, new crackles on lung auscultation, increasing oxygen requirements, jugular venous distension, or new peripheral edema. This is especially relevant with 5% albumin given at higher rates.
Hemodynamic changes: a fall in blood pressure during the infusion can indicate a reaction, while a progressive rise might signal volume overload. Heart rate changes often accompany either problem.

Albumin is a plasma-derived product, so serum albumin levels can be checked after the infusion to assess whether the dose achieved the desired effect. In patients receiving albumin for hypoalbuminemia, a repeat level drawn 6 to 12 hours after the infusion gives a reasonable picture. Drawing it too soon overestimates the lasting benefit because some of the protein redistributes out of the vascular space over the following hours.

Serious but Uncommon Adverse Events

True anaphylaxis from albumin is rare, but it happens. One documented case involved a patient who went into anaphylactic shock during cardiac surgery, with human serum albumin confirmed as the trigger through skin testing.³ An interesting wrinkle is that some patients react to albumin from one manufacturer but tolerate it from another. Two reported cases showed allergic symptoms that resolved completely after switching brands, suggesting the reaction was to something in that particular formulation rather than to the albumin protein itself.⁴ If a patient develops a reaction and needs ongoing albumin therapy, trying a different manufacturer before abandoning the product entirely is a reasonable step.

Transfusion-related acute lung injury, or TRALI, has been reported after albumin infusion in patients with liver disease. One case involved a patient who developed sudden respiratory failure with imaging findings consistent with pulmonary edema, yet without other signs of volume overload. The patient improved with supportive care.⁵ TRALI is far more commonly associated with plasma and platelet transfusions than with albumin, but clinicians should be aware that it is in the differential when a patient deteriorates during or shortly after an albumin infusion.

Common Clinical Scenarios and Dosing

Albumin administration is not one-size-fits-all. The dose, concentration, and urgency differ substantially depending on why the patient needs it.

Large-Volume Paracentesis

When more than about 5 liters of ascitic fluid are drained from a patient with cirrhosis, the sudden shift in intra-abdominal pressure can trigger a drop in effective circulating volume known as paracentesis-induced circulatory dysfunction, or PICD. The standard prevention strategy is to infuse 6 to 8 grams of albumin (usually 25%) for every liter of fluid removed. A randomized trial in patients with acute-on-chronic liver failure found that even with smaller-volume paracentesis (under 5 liters), PICD occurred in about 70% of patients who did not receive albumin, compared with roughly 30% of those who did.⁶ The albumin is typically started during or immediately after the procedure and infused over one to two hours.

Spontaneous Bacterial Peritonitis

In patients with cirrhosis who develop spontaneous bacterial peritonitis (SBP), albumin is given alongside antibiotics to prevent kidney failure. A landmark trial used a weight-based protocol: 1.5 grams per kilogram of body weight at the time of diagnosis, followed by 1 gram per kilogram on day 3.⁷ For a 70-kilogram patient, that works out to 105 grams on day one and 70 grams on day three, which is a substantial amount of albumin. The 25% formulation is almost always used here to keep total fluid volume manageable in patients who are already prone to fluid retention.

Sepsis and Septic Shock

The role of albumin in sepsis resuscitation has been debated for years. A large European trial comparing albumin-targeted resuscitation with crystalloid alone in patients with severe sepsis found no difference in mortality at 28 days, though the albumin group had slightly higher mean arterial pressures and lower net fluid balance.⁸ A more recent trial focused specifically on septic shock also found no significant survival benefit with albumin, though it was stopped early and the authors called the results inconclusive.⁹

However, a 2026 systematic review and meta-analysis pooling data from randomized trials found that albumin-based resuscitation was associated with a roughly 10% reduction in relative mortality risk in patients with septic shock specifically. The authors rated the overall certainty of the evidence as low, meaning the direction of benefit is plausible but not firmly established.¹⁰ The bottom line in practice: albumin is considered safe in sepsis and may help in septic shock, but it has not yet achieved the level of evidence needed to make it a universal recommendation over crystalloid alone.

Albumin Versus Synthetic Colloids

Before albumin became the colloid of choice in many settings, hydroxyethyl starch (HES) solutions were widely used for volume expansion. That landscape shifted substantially after evidence linked HES to kidney damage. A systematic review of HES in sepsis patients found that those receiving HES needed kidney replacement therapy at higher rates compared with those given crystalloid or albumin.¹¹ A similar safety signal appeared in cardiac surgery patients primed with HES versus albumin on cardiopulmonary bypass, where HES was associated with a higher risk of acute kidney injury.¹²

An animal model of septic shock compared albumin, HES, and crystalloid directly and found that albumin-resuscitated subjects had better urine output and creatinine clearance than untreated controls, while HES did not outperform crystalloid on those renal markers.¹³ HES products have been withdrawn or restricted in many countries as a result of these findings. Albumin remains the primary colloid alternative to crystalloids in critically ill patients who need one.

Cost and Supply Realities

Albumin is a human plasma-derived product, which makes it inherently more expensive than crystalloid solutions. A 500 mL bag of normal saline costs a few dollars at most, while the same volume of 5% albumin can cost dozens of times more, and 25% albumin is pricier still per unit volume. These cost differences are clinically relevant. Economic analyses in sepsis populations have attempted to weigh the potential hemodynamic benefits of albumin against the higher expense.¹⁴ The answer depends heavily on the healthcare system, the clinical indication, and the patient’s baseline albumin level. In practice, many hospitals restrict albumin use to approved indications (SBP, large-volume paracentesis, severe septic shock with documented hypoalbuminemia) rather than letting it be used freely as a resuscitation fluid.

Supply can also be a constraint. Because albumin is fractionated from donated human plasma, its availability depends on plasma collection volumes. Shortages occur periodically, and when they do, hospitals typically tighten criteria for use even further. Knowing the approved indications and having crystalloid-based backup plans matters for clinicians who regularly administer this product.

How Pathogen Safety Is Achieved

A common question from patients, and sometimes from clinicians who are newer to blood products, is whether albumin can transmit infections. The short answer is that the risk is extraordinarily low, thanks to the manufacturing process. Albumin undergoes pasteurization, typically at 60°C for 10 hours, which inactivates the vast majority of viruses.¹⁵ This heat treatment has been part of albumin production for decades and is the reason no confirmed case of HIV, hepatitis B, or hepatitis C transmission through commercially produced albumin has been documented in the modern era.

Even for newer viral threats, the pasteurization step provides a robust safety margin. Testing during the Zika virus outbreak showed that the standard heat treatment reduced Zika viral load by more than seven log-steps in 25% albumin, and in some conditions the virus was inactivated before the formal pasteurization temperature was even fully reached.¹⁶¹⁷ Some non-enveloped viruses are harder to kill with heat alone, and manufacturers have explored combining high pH with pasteurization to address that gap. Overall, albumin is considered one of the safest plasma-derived products from an infection standpoint.

Practical Tips That Textbooks Often Skip

A few hands-on points that experienced nurses and pharmacists will recognize but that rarely make it into formal protocols:

Foaming: albumin foams when shaken. Vigorous agitation of the bottle or bag can introduce air bubbles and make priming the tubing more difficult. Handle gently and invert rather than shake.
Line compatibility: do not run albumin through the same line as certain medications without checking compatibility. Lipid emulsions, vancomycin, and midazolam are among the drugs known to be incompatible with albumin in Y-site administration. When in doubt, run it through a dedicated line or flush thoroughly between infusions.
Documentation: because albumin is a blood product in regulatory terms, many facilities require the same documentation as for packed red blood cells: two-nurse verification of the product at the bedside, recording of lot number and expiration, and documentation of any reactions in the transfusion record.
Repeat dosing: in conditions like SBP or hepatorenal syndrome, albumin is often given on multiple days. Track cumulative doses carefully. A patient receiving the SBP protocol can easily receive over 150 grams of albumin across just two doses, and fluid shifts from that amount are significant.

Albumin administration sits at the intersection of pharmacy, nursing, and physician decision-making. The setup is straightforward compared to many blood products, but the details around concentration selection, diluent safety, rate adjustments for vulnerable patients, and indication-specific dosing require attention that a simple “hang and run” approach cannot provide.